Budget Impact Test
NHS supremo hails Alexion and Roche deals, but defends budget controls
Alexion, BIA, Brexit, Budget Impact Test, MHRA, NHS England, Simon Stevens
0 Comment
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Ultra-rare disease drugs: has access in England just got harder?
Budget Impact Test, market access, NHS England, NICE, Rare diseases
0 Comment
Gaining access to ultra-orphan drugs could become much more difficult.
Pharma could take NHS England to court over new delaying tactics
Budget Impact Test, NHS, NHS England, UK market access
0 Comment
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
Pharma criticises ‘heavy handed’ NICE affordability test
AbbVie, Budget Impact Test, cost-effectiveness, drug spend, Gilead, NHS, NICE
0 Comment
NHS England and NICE are attempting to reduce budget impact of drugs.
The budget impact of new medicines
Budget Impact Test, Drug funding, HTA, market access, NHS, NHSE, NICE, PPRS, Technology Appraisal
0 Comment
What could be the impact of proposed new ‘budget impact threshold’ for drugs?